Condition
Stage IV Major Salivary Gland Cancer AJCC v7
Total Trials
2
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT00588770Phase 3Active Not Recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00859937Phase 2Completed
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Showing all 2 trials